Biosimilar Notice Always Mandatory, Fed. Circ. Rules
The Federal Circuit on Tuesday ruled that biosimilar makers must always notify brand-name rivals six months before launching their products, a major decision that may delay lower-cost competition for pricey biologics....To view the full article, register now.
Already a subscriber? Click here to view full article